Oligo- and hypofractionated stereotactic radiotherapy of lung cancer  by Dziadziuszko, R.
	  
	  
toxicity profiles depending on the size and location of 
metastatic sites. Clinical data indicate that the number of 
patients with oligometastatic disease receiving aggressive 
treatments is increasing rapidly. The distinct biological 
behavior of tumors with oligometastatic spread is currently 
explored by a number of groups. 
The most robust verification of ablative oligometastasis-
directed therapy has been documented in patients with 
limited intracranial metastases for which systemic treatment 
had limited efficacy. Randomized studies have demonstrated 
that surgical resection or radiosurgery can improve overall 
survival when added to whole-brain irradiation. Randomized 
evidence also exists for surgical resection of metastases, not 
solely in patients with oligometastases, causing epidural 
spinal cord compression. Outside of the central nervous 
system, limited randomized evidence exists to guide 
therapeutic decisions for patients with oligometastases. Most 
practice patterns are guided by large, single-institution or 
pooled series of patients demonstrating favorable survival. 
Limited number of studies with adequate controls raise the 
possibility that this survival gain might not be due to 
treatment effect, but rather due to patient selection 
criteria. For the widespread acceptance of oligometastatic 
ablative treatment, stronger evidence supporting its efficacy 
is needed. 
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As a result of two decades of research, hypofractionated 
stereotactic radiotherapy of stage I non-small cell lung 
cancer (NSCLC) is now established as a standard of care in 
patients who are not candidates for surgical treatment. As 
demonstrated in large series of patients treated with SBRT 
for NSCLC, locoregional control exceeds 80% at 5-years, 
which appears comparable to surgical outcomes. SBRT 
programs became available in most European countries and 
centers, including several institutions in Poland. 
Implementation of successful SBRT program must focus on 
4D-CT imaging, co-registered with repeatable breath cycle, 
careful GTV and PTV delineation taking into account 
respiratory motion, treatment planning using advanced B-
type algorithms  by experienced physicists, image guided 
treatment delivery, and implementation of strict quality 
control measures. Most common treatment schedules include 
54Gy in 3 fractions, 55Gy in 5 fractions and 60Gy in 8 
fractions, depending on tumor location and proximity of 
organs-at-risk. Current research efforts exploring SBRT for 
lung cancer include clinical trials in patients who are 
considered for surgery, management of centrally located 
tumors, clinical and radiological patterns of disease 
recurrence, clinical and molecular prognostic factors and 
assessment of systemic therapies, including immunotherapies 
and targeted agents. Other studies evaluate the addition of 
SBRT as a boost to conventionally fractionated 
radiochemotherapy for stage II – III NSCLC. 
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Only relatively small proportion of hepatic tumors can be 
safely resected. Modern radiation treatment techniques can 
enhance, thus, therapeutic options beyond palliative 
systemic treatment or other local ablative techniques. The 
data from the literature indicate that stereotactic body 
radiation therapy (SBRT) can offer satisfactory rate of local 
control both in primary hepatocellular cancer (HCC) or liver 
metastases (LM). Total radiation dose  of 45 Gy or more and 
target diameter of less than 5 cm are among the factors 
related to favorable local control. Review of the published 
data indicate that local control at 1-2 years can, in general, 
exceed 70% in properly selected groups of patients. 
Respiratory motion of the liver provides a challenge in 
delivery of high radiation dose to the tumor demanding 
expansion of irradiated volume to encompass movements of 
the tumor. To address this problem special radiation 
techniques are used including respiratory gating, tracking or 
abdominal compression. Such techniques allow to minimize 
the margins and reduce, thus, the dose delivered to the 
normal tissue that surrounds the tumor. In spite of high local 
control rates overall survival of patients with hepatic tumors 
treated with SBRT is not satisfactory, mostly because of 
distant failures. This illustrates urgent need to develop new 
treatment strategies that would better integrate available 
local and systemic therapies. 
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Introduction: Prostate cancer (PC) is one of most common 
malignancies. Large percentage of PC patients is treated with 
radiotherapy (RT). The main problem connected to 
conventional radiotherapy is long overall treatment time 
(OTT) ranging to 8 weeks, so many attempts of OTT shrinkage 
are done. The one of them is CyberKnife based radioablation 
allowing to complete the therapy within 5-9 days. 
Material: 200 PC patients aged from 53 to 83 (mean 69)  
irradiated every other day using fd of 7.25 Gy to TD of 36.25 
Gy (OTT 9 days). 95 were from low risk, 104 from 
intermediate risk (excluding Gleason 4+3) and 1 from high 
risk group. The maximal PSA varied from 1.05 to 50.3 (mean 
8.6, median 7.6). T stage varied from T1c to T2c. Means of 
prostate dimensions before the treatment were 
42.5x37.5x40.4 mm for X, Y and Z axes respectively. 
Method: After treatment completion, 1, 4, 8 months later 
and next every each 6 months up to 26 months the 
percentage of patients using hormonal drugs (HT), GI (gastro-
intestinal) and GU (genito-urinary) toxicity using 
EORTC/RTOG scale (acute up to 4th month and next late) and 
PSA were checked. 
Results: Results obtained during FU are presented in the 
Table. 
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